Silvia Franze
Overview
Explore the profile of Silvia Franze including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
455
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dattilo M, Patitucci F, Motta M, Prete S, Galeazzi R, Franze S, et al.
Colloids Surf B Biointerfaces
. 2024 Nov;
247():114408.
PMID: 39615428
Emerging zoonoses pose significant public health risks and necessitate rapid and effective treatment responses. This study enhances the technology for preparing Molecularly Imprinted Polymers (MIPs), which function as synthetic nanoparticles...
2.
Vincenti S, Villa A, De Mitri Z, Maiolini A, Franze S, Schweizer D, et al.
Vet Comp Oncol
. 2024 Sep;
22(4):621-628.
PMID: 39313755
Canine and human brain tumours exhibit similar incidence rates and prognoses. Recent studies have demonstrated that extracellular vesicles derived from human patients (PDEVs) can be loaded with contrast agents and...
3.
Franze S, Rama F, Scarpa E, Violatto M, Peqini K, Gennari C, et al.
Int J Pharm
. 2024 Jul;
661:124413.
PMID: 38960342
Local drug delivery to the esophagus is hampered by rapid transit time and poor permeability of the mucosa. If some strategies aimed to improve the residence time have been proposed,...
4.
Musazzi U, Franze S, Condorelli F, Minghetti P, Caliceti P
Adv Healthc Mater
. 2023 Sep;
12(30):e2301956.
PMID: 37718353
New and innovative nanomedicines have been developed and marketed over the past half-century, revolutionizing the prognosis of many human diseases. Although a univocal regulatory definition is not yet available worldwide,...
5.
Franze S, Ricci C, Del Favero E, Rama F, Casiraghi A, Cilurzo F
Mol Pharm
. 2023 Jun;
20(7):3393-3402.
PMID: 37306238
Deformable liposomes represent valuable drug carriers for cutaneous administration. Nevertheless, the fluid lipid membrane can favor the drug leakage during storage. Proliposomes may represent a suitable strategy to solve this...
6.
Crisafulli S, Cutroneo P, Luxi N, Fontana A, Ferrajolo C, Marchione P, et al.
Drug Saf
. 2023 Feb;
46(4):343-355.
PMID: 36790561
Background And Objective: Evidence highlights the allergenic potential of PEGylated drugs because of the production of anti-polyethylene glycol immunoglobulins. We investigated the risk of hypersensitivity reactions of PEGylated drugs using...
7.
Selmin F, Franze S, Casiraghi A, Cilurzo F
Pharmaceutics
. 2022 Oct;
14(10).
PMID: 36297520
Psoriasis is a lifelong disease which requires treatment adherence for successful management. Considering the complexity of this pathology, the combination of active pharmaceutical ingredients with a synergistic mechanism of action...
8.
Franze S, Angelo L, Casiraghi A, Minghetti P, Cilurzo F
Pharmaceutics
. 2022 Sep;
14(9).
PMID: 36145663
The administration of drug fixed combinations by nanocarriers is a new attractive approach since it can allow improvements in both the skin penetration of cargo compounds and their synergistic effects....
9.
Milan Bonotto R, Boni F, Milani M, Chaves-Sanjuan A, Franze S, Selmin F, et al.
Viruses
. 2022 Jun;
14(6).
PMID: 35746629
Pyridobenzothiazolone derivatives are a promising class of broad-spectrum antivirals. However, the mode of action of these compounds remains poorly understood. The HeE1-17Y derivative has already been shown to be a...
10.
Schlich M, Musazzi U, Campani V, Biondi M, Franze S, Lai F, et al.
Drug Deliv Transl Res
. 2021 Nov;
12(8):1811-1828.
PMID: 34755281
The skin is the absorption site for drug substances intended to treat loco-regional diseases, although its barrier properties limit the permeation of drug molecules. The growing knowledge of the skin...